Uganda
Tuberculosis profile
| High TB burden | High HIV burden |
Population  2012 36 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4.7 (0.82–12) 13 (2.3–33)
Mortality (HIV+TB only) 9.2 (8–12) 25 (22–32)
Prevalence  (includes HIV+TB) 64 (24–120) 175 (67–334)
Incidence  (includes HIV+TB) 65 (53–79) 179 (145–216)
Incidence (HIV+TB only) 35 (28–42) 95 (77–115)
Case detection, all forms (%) 69 (57–85)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 24 916 (58) Relapse 1 334 (34)
Smear-negative 11 487 (27) Treatment after failure 270 (7)
Smear-unknown / not done 1 783 (4) Treatment after default 1 164 (30)
Extrapulmonary 5 143 (12) Other 1 114 (29)
Other 0 (0)      
Total new 43 329   Total retreatment 3 882  
           
Other (history unknown) 0        
Total new and relapse 44 663   Total cases notified 47 211  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.8    
Age < 15 636    
Laboratories 2012
Smear (per 100 000 population) 3.2
Culture (per 5 million population) 0.6
Drug susceptibility testing (per 5 million population) 0.6
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 77   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 66  
Retreatment 71  
TB/HIV 2012 Number (%)
TB patients with known HIV status 40 581 (86)
HIV-positive TB patients 20 376 (50)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 19 163 (94)
HIV-positive TB patients on antiretroviral therapy (ART) 9 962 (49)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.4 (0.6–2.2) 12 (6.8–19)
MDR-TB cases among notified pulmonary
TB cases
540 (230–860) 470 (260–750)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 196 (<1%) 748 (19%) 1 406
Laboratory-confirmed MDR-TB cases 9 71 89
Patients started on MDR-TB treatment     41
Financing TB control 2013
National TB programme budget (US$ millions) 31
% Funded domestically 7%
% Funded internationally 62%
% Unfunded 31%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data